ProQR Uses Causaly to Support Target Identification For Axiomer™ Platform

ProQR faced challenges with bandwidth, aggressive targets, and the overwhelming growth of biomedical literature. Causaly's AI platform accelerated ProQR’s R&D by enabling faster review of publications and allowing their team to make more informed decisions. Read the case study below to learn how ProQR met their 2024 target ID goal by Q3 and achieved 5x productivity compared to using PubMed.

Challenges before Causaly

Limited Bandwidth

ProQR’s R&D team is responsible for multiple projects, so they often juggle multiple research streams.

Ambitious Target Hunting Goals

ProQR was looking to identify many high conviction targets to demonstrate breadth of application of their Axiomer™ platform.

Cutting through the Noise

With the exponential growth of biomedical literature, ProQR wanted to ensure they weren’t missing critical evidence.

Causaly helped us unearth more hidden links much faster than if we were to go through the paper, read it, and hope the author mentions what we are interested in. PubMed wouldn’t be a substitute. - Bart Klein, SVP Head of Axiomer Strategy

Causaly solutions

Faster R&D

ProQR quickly reviewed many more publications with AI-generated summaries, to explain relationships and phenomena they had observed in studies, accelerating progress within their current pipeline at a rate that was previously not possible with PubMed.

Uncovering New Insights

Using Causaly’s high-precision knowledge graph, ProQR was able to find hidden connections and facilitate the identification of target indications already in the pipeline while also revealing new research angles.

Stronger, More Informed Decisions

ProQR accelerated target ID and selection processes and uncovered critical insights around safety concerns, which helped them make go/no-go decisions during target validation.

The results

2024 target ID goal met by Q3

50% of the targets ProQR pitched in Q3 were informed by Causaly insights

5x more productive than using PubMed

AI capabilities enabled review of more relevant and higher number of publications

Get to know Causaly

What would you ask the team behind life sciences’ most advanced AI? Request a demo and get to know Causaly.

Request a demo